TICKERNERD
Menu
OABIOABIHealthcare · Biotechnology

OABI Stock Forecast: OmniAb, Inc. Price Predictions for 2026-2027

Last close, 5 Nov 2026
$4.83
−6.76% on the day

The 7 Wall Street analysts covering OmniAb, Inc. hold a median 12-month price target of $8 — +65.6% from the last close. Ticker Nerd's systematic factor model, run across ~4,600 US stocks, ranks it 99 of 100 as at 5 Nov 2026 — among the strongest tenth. Here, the model and the Street point the same way.

Market cap
$751.2M
Ticker Nerd rank
99/ 100
Median analyst target
$8.00
Analysts covering
7
Revenue$13.4M+244.2% y/y
Operating income−$6.6M
Net income−$5.9M
Free cash flow$2.6M
Quarterly, 8 quarters to 30 June 2026 · latest quarter's figure shown
Total return, dividends reinvested
1W
−7.6%
1M
−1.8%
YTD
+161.1%
1Y
+238.9%
From 52W high
−8.5%
From 52W low
+255.1%
$1.36
$5.28
52-week range, adjusted closes · the dot is the last close
Ticker Nerd rank

OABI stock analysis: one number for the whole business

Consensus tells you what everyone already believes. The model scores OmniAb, Inc. on its factor families — the same systematic rank behind the Ticker Nerd portfolio.

Where the model ranks itAs at 5 Nov 2026
99/ 100

Percentile across ~4,600 US stocks on Ticker Nerd’s systematic factor model. Higher is better. How the model is built and tested

Momentum
99
Growth
95
Revisions
95
Accruals
94
Value
73
Issuance
66
Quality
65
Size
48
Volatility
35

Momentum (99): The shares have been drifting up relative to others.

Volatility (35): The share price moves around a lot.

Built and run by Aslam Ghouse, an ex-Goldman Sachs systematic trader with 15+ years in markets.

Wall Street

OABI stock forecast 2026-2027: analyst price targets & predictions

The bullish and bearish analyst opinions on OABI, reported as data — targets and ratings, the market's view beside the model's.

Share price and the analyst range, 12 monthsAdjusted close, US dollars
$0.00$2.00$4.00$6.00$8.00$10.00$12.00Jan 26Apr 26Jul 26Oct 26OABIHigh $12.00Median $8.00Low $5.00

Price targets and ratings are third-party analyst estimates, reported here as data. They are not Ticker Nerd forecasts, and they are frequently wrong.

Data provided by Twelve Data

What Wall Street says7 analysts
7 Buy0 Hold0 Sell
Low $5.00Median $8.00High $12.00

The green dot is the last close — the median target sits +65.6% from it.

Recent analyst actionsNewest first

Of the 20 most recent actions, 2 moved their price target up and 1 moved it down.

DateFirmActionRatingTarget
7 Oct 2026Leerink PartnersMaintainsOutperform$10 → $12
7 Oct 2026StoneXMaintainsBuy$4.00 → $6.00
17 Aug 2026HC Wainwright & Co.ReiteratesBuy$11
17 Aug 2026HC Wainwright & Co.ReiteratesBuy—
7 Aug 2025RBC CapitalMaintainsOutperform—
7 Aug 2025RBC CapitalMaintainsOutperform$4.00 → $3.00
12 May 2025BenchmarkReiteratesBuy—
27 Mar 2025RBC CapitalMaintainsOutperform—
20 Mar 2025BenchmarkMaintainsBuy—
19 Mar 2025HC Wainwright & Co.ReiteratesBuy—
14 Nov 2024BenchmarkReiteratesBuy—
14 Nov 2024HC Wainwright & Co.ReiteratesBuy—
19 Aug 2024BenchmarkReiteratesBuy—
16 Aug 2024RBC CapitalReiteratesOutperform—
12 Aug 2024HC Wainwright & Co.ReiteratesBuy—
14 May 2024BenchmarkReiteratesBuy—
26 Mar 2024Truist SecuritiesMaintainsBuy—
22 Mar 2024BenchmarkReiteratesBuy—
21 Mar 2024HC Wainwright & Co.ReiteratesBuy—
21 Mar 2024RBC CapitalReiteratesOutperform—

Price targets and ratings are third-party analyst estimates, reported here as data. They are not Ticker Nerd forecasts, and they are frequently wrong.

Market Radar

This page is one stock. Monday covers all of them.

OABI appears in the Radar on the weeks it earns a place.

  • Market Radar, every Monday: the week's biggest rank moves across ~4,600 US stocks, and the reason for each.
  • The AI build-out map, free: every AI company we track, part by part, and one part in full with each verdict.

Free. Unsubscribe any time.

The AI build-out map
PDF

  • AI cloud capacity

    MSFTAMZNGOOGLORCL

  • AI chips

    NVDAAVGOAMDMU

  • AI networking and serversIn full

    ANETDELLLITECRDO

  • Data centre power

    VRTCEGGEVVST

Performance

OABI vs the S&P 500

Both lines are total return — dividends reinvested — so the comparison is honest on both sides.

Over the twelve months to 5 Nov 2026, OmniAb, Inc. returned +238.9% against +9.3% for the S&P 500, dividends included.

OABI vs S&P 500, last 12 monthsTotal return, rebased to 100
50100150200250300350400Jan 26Apr 26Jul 26Oct 26OABIS&P 500

Download this chart as an image — free to reuse; link this page as the source.

Data provided by Twelve Data

Estimates

OABI analyst estimate revisions

Not the forecast itself — the direction analysts are revising it. Revision direction is one of the model's factor families.

Which way the estimates are movingThis fiscal year
Analysts raising
5
Analysts cutting
0
Fundamentals

OmniAb, Inc. (OABI) financial data

A margin means little on its own. Each bar marks where the figure sits across the whole US universe we score.

Valuation
Trailing P/E
−9.0×

Cheaper than 93% of US stocks

Price / sales
18.7×

Cheaper than 8% of US stocks

Price / book
3.0×

Cheaper than 30% of US stocks

EV / EBITDA
−34.7×

Cheaper than 93% of US stocks

Growth & margins
Revenue growth (YoY)
78.3%

Higher than 90% of US stocks

Earnings growth (YoY)
244.2%

Higher than 92% of US stocks

Gross margin
95.5%

Higher than 98% of US stocks

Operating margin
−409.9%

Higher than 8% of US stocks

Net margin
−108.1%

Higher than 5% of US stocks

Returns & dividend
Return on equity
−16.5%

Higher than 33% of US stocks

Return on assets
−7.8%

Higher than 29% of US stocks

Dividend yield
0.0%

Higher than 1% of US dividend payers

Bars mark the percentile across the ~4,600 US stocks Ticker Nerd covers, among those reporting the figure.

Key statistics

OmniAb, Inc. (OABI) statistics: revenue, profit & scale

The headline figures, each with its date. Every row carries its own link — cite it straight from here.

  • OmniAb, Inc. has a market value of $751.2M and an enterprise value of $705.1M.

  • Revenue in the twelve months to 30 June 2026: $38.5M. The latest quarter grew 78.3% year on year.

  • Net income over the same four quarters: −$44.3M, a −115.1% net margin.

  • Diluted earnings per share, trailing twelve months: $−0.36.

  • Free cash flow in the twelve months to 30 June 2026: −$18.1M.

  • Shares outstanding: 145.4M.

  • Trailing P/E: −9.0×; forward P/E: −19.8× — the forward figure prices analyst consensus estimates, not reported earnings.

  • Forward dividend yield: 0.00%, paying out 0% of earnings.

  • OmniAb, Inc. employs 89 people — $432K of revenue per employee.

Statement figures: company filings via Twelve Data, four quarters to 30 June 2026 · market figures as at 4 Nov 2026

Data provided by Twelve Data

Peers

OABI vs competitors

The nearest names by industry and size, scored by the same model — like for like.

Its peer group, ranked by the same modelBiotechnology
CompanyMarket capTKN rank
OABIOmniAb, Inc.$751.2M99
SANASana Biotechnology, Inc.$700.5M33
SLDBSolid Biosciences, Inc.$689.8M45
LXRXLexicon Pharmaceuticals, Inc.$716.4M69
ATTOAttovia Therapeutics, Inc.$683.7M0
ABUSArbutus Biopharma Corp.$722.8M92
CGEMCullinan Therapeutics, Inc.$663.7M72

Look up any of the roughly 4,600 stocks we score.

The rank is the raw material. Whether the rules would actually own OmniAb, Inc. — and when they’d sell — is the membership. See the Ticker Nerd 20 →

News

Latest OABI news & analysis

OmniAb: A Self-Funding Option Book On 433 Partner Programs

Seeking Alpha · 1 Nov 2026positive

Seeking Alpha reports that OmniAb has reached self-sustaining cash flow and projects break-even net cash usage in 2026. The article highlights its 433 partner programs, potential milestones and royalties, Lilly ion channel partnership, and possible clinical readouts through 2027.

Why it matters — OABI watchers may care about the reported funding position and the scale and timing of potential pipeline-related milestones and readouts.

OmniAb, Inc. (OABI) Q3 2026 Earnings Call Transcript

Seeking Alpha · 30 Oct 2026neutral

Seeking Alpha published a transcript of OmniAb, Inc.’s Q3 2026 earnings call. The excerpt provides no details about the discussion.

Why it matters — OABI watchers can note the availability of the quarterly call transcript, though the excerpt contains no operating or financial updates.

OmniAb Q3 Earnings Call Highlights

MarketBeat · 30 Oct 2026positive

OmniAb reported higher third-quarter revenue and raised its full-year 2026 revenue and year-end cash outlook. The company cited partner-program milestones, growing service revenue and early commercial progress for its xPloration B-cell screening platform.

Why it matters — The update highlights revenue growth and improved outlook alongside progress in partner programs, services and its screening platform.

OmniAb, Inc. (OABI) Reports Q3 Loss, Tops Revenue Estimates

Zacks Investment Research · 30 Oct 2026neutral

OmniAb reported a quarterly loss of $0.12 per share, in line with the Zacks Consensus Estimate, compared with a loss of $0.14 per share a year earlier. The headline also says the company topped revenue estimates.

Why it matters — OABI watchers may note the per-share loss was narrower than a year ago, while matching consensus estimates.

OmniAb Reports Third Quarter 2026 Financial Results and Business Highlights

Business Wire · 30 Oct 2026positive

OmniAb reported financial results for the three and nine months ended September 30, 2026, shared operating and partner program progress, and updated its 2026 financial guidance. The company characterized its third-quarter performance as strong, citing licensing execution and a focus on stakeholder value and efficiency.

Why it matters — OABI watchers may be interested in the reported results, partner-program progress, and revised 2026 guidance.

FAQ

Frequently asked questions about OABI stock

What is the OABI stock price forecast for 2026-2027?

The 7 Wall Street analysts covering OmniAb, Inc. have a median 12-month price target of $8, with estimates ranging from $5 to $12. These are third-party analyst estimates, not Ticker Nerd forecasts, and they are frequently wrong.

Is OABI stock a buy right now?

Of the 7 analysts covering OmniAb, Inc., 7 rate it a Buy, 0 a Hold and 0 a Sell. Ticker Nerd's systematic factor model ranks OmniAb, Inc. 99 out of 100 across roughly 4,600 US stocks as at 5 Nov 2026. None of this is personal advice — it does not consider your circumstances.

How does Ticker Nerd's model rank OABI?

As at 5 Nov 2026, OmniAb, Inc. ranks 99 out of 100 on Ticker Nerd's systematic factor model — a percentile across roughly 4,600 US stocks, built from its factor families. Its strongest factor family is Momentum (99 of 100).

Will OABI stock go up?

No one can know that. What the data says: the median 12-month target from 7 analysts implies +65.6% from the last close, and Ticker Nerd's factor model ranks OmniAb, Inc. 99 out of 100 as at 5 Nov 2026. Analyst targets are third-party estimates and frequently wrong; none of this is personal advice.

What is the OABI stock forecast for 2030?

No analyst covering OmniAb, Inc. publishes a 2030 price target — Wall Street targets run 12 to 18 months out. Sites quoting a 2030 price for OABI are extrapolating price history, which says nothing about the business. The furthest attributed numbers are the current analyst targets: $5 to $12 over the next 12 months.

How has OABI stock performed over the past year?

OmniAb, Inc. returned +238.9% over the 12 months to 5 Nov 2026, with dividends reinvested. Past performance does not indicate future returns.

What does OmniAb, Inc. do?

OmniAb, Inc. is a biotechnology company that licenses discovery research technology to pharmaceutical and biotech companies and academic institutions.

What is the latest news on OABI?

The most recent item we track (Seeking Alpha, 1 Nov 2026): "OmniAb: A Self-Funding Option Book On 433 Partner Programs". Seeking Alpha reports that OmniAb has reached self-sustaining cash flow and projects break-even net cash usage in 2026. The article highlights its 433 partner programs, potential milestones and royalties, Lilly ion channel partnership, and possible clinical readouts through 2027.

Company

About OmniAb, Inc.

OmniAb, Inc. is a biotechnology company that licenses discovery research technology to pharmaceutical and biotech companies and academic institutions. OmniAb’s platform is designed to support the discovery of next-generation therapeutics by creating and screening diverse antibody repertoires, helping partners identify optimal antibodies and other target-binding proteins for drug development. Its current offerings center on proprietary transgenic animal systems and related discovery tools that enable the generation of fully human antibodies and other therapeutic candidates. The company also provides integrated and customizable solutions that combine biological and computational methods, including antigen design, immunization, high-throughput screening, and data analysis. OmniAb serves a broad range of partners across the life sciences industry, positioning itself as a technology provider in the antibody discovery and biologics research market. Headquartered in Emeryville, California, OmniAb focuses on enabling research programs rather than developing and commercializing its own drugs.

CEO Mr. Matthew W. Foehr · 89 employees · United States · https://www.omniab.com